These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25145430)

  • 101. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
    Jang M; Simoens S; Kwon T
    BioDrugs; 2021 Jan; 35(1):89-101. PubMed ID: 33368051
    [TBL] [Abstract][Full Text] [Related]  

  • 102. [Recombinant proteins as therapeutic compounds in clinical oncology].
    Fey MF
    Ther Umsch; 2011 Nov; 68(11):618-30. PubMed ID: 22045524
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs.
    Grampp G; McElroy PL; Camblin G; Pollock A
    J Pharm Sci; 2018 Jun; 107(6):1512-1520. PubMed ID: 29408510
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
    Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
    JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
    [No Abstract]   [Full Text] [Related]  

  • 105. New York University Medical Center's pilot "Epo-Depot" program: a win-win for patients and health care.
    Smith D; Delmore B
    J Assoc Nurses AIDS Care; 2004; 15(6):23-30. PubMed ID: 15538014
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 107. A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada.
    Tsao NW; Lo C; Leung M; Marin JG; Martinusen D
    Can J Kidney Health Dis; 2014; 1():28. PubMed ID: 25780617
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Implementing and Optimizing Biosimilar Use at Mayo Clinic.
    Jensen CJ; Tichy EM; Lempke MB; Ewald AM; Erickson SJ; Holm MR; Soefje SA
    Mayo Clin Proc; 2022 Jun; 97(6):1086-1093. PubMed ID: 35337661
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Budget Impact Analysis of Switching to Rituximab's Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa.
    Almaaytah A
    Clinicoecon Outcomes Res; 2020; 12():527-534. PubMed ID: 32982342
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Benefits of epoetin alfa therapy in anemic cancer patients receiving chemotherapy.
    Henry DH; Abels RI
    J Clin Oncol; 1995 Sep; 13(9):2473-4. PubMed ID: 7666110
    [No Abstract]   [Full Text] [Related]  

  • 111. Primum non nocere.
    Templeton AJ; Šeruga B
    Ann Oncol; 2015 Oct; 26(10):2197-8. PubMed ID: 26169770
    [No Abstract]   [Full Text] [Related]  

  • 112. Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.
    Arnlind MH; Fryklund L; Vitols S; Bertilsson G
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1161-1169. PubMed ID: 27444173
    [TBL] [Abstract][Full Text] [Related]  

  • 113. How do biosimilars sustain value, affordability, and access to oncology care?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
    [No Abstract]   [Full Text] [Related]  

  • 114. Development of biosimilars in an era of oncologic drug shortages.
    Li E; Subramanian J; Anderson S; Thomas D; McKinley J; Jacobs IA
    Drug Des Devel Ther; 2015; 9():3247-55. PubMed ID: 26150698
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Insights and perspectives in the clinical and operational management of cancer-related anemia.
    Hinkel JM; Li EC; Sherman SL
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S38-55. PubMed ID: 20947722
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.
    Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
    Ann Oncol; 2015 Oct; 26(10):2198-9. PubMed ID: 26153497
    [No Abstract]   [Full Text] [Related]  

  • 117. Recombinant human erythropoietin in chemotherapy-associated anemia.
    Cascinu S; Catalano G; Cellerino R
    Cancer Treat Rev; 1996 Nov; 21(6):553-64. PubMed ID: 8599805
    [No Abstract]   [Full Text] [Related]  

  • 118. Empower physicians to fight financial toxicity with biosimilars.
    Oubre K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
    [No Abstract]   [Full Text] [Related]  

  • 119. The rise of biosimilars in cancer care.
    Roe H
    Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369
    [No Abstract]   [Full Text] [Related]  

  • 120. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
    Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
    Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.